Related Experiment Videos
Lymph node staging in lung cancer using [18F]FDG-PET
G Halter1, A K Buck, H Schirrmeister
1Department of Thoracic and Vascular Surgery, University of Ulm, Ulm, Germany. gisela.halter@medizin.uni-ulm.de
The Thoracic and Cardiovascular Surgeon
|April 23, 2004
Summary
Positron emission tomography (PET) using 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG) is a superior, noninvasive method for staging lung cancer lymph nodes compared to computed tomography (CT). FDG-PET accurately identifies mediastinal nodal metastases, aiding treatment decisions.
Area of Science:
- Oncology
- Radiology
- Nuclear Medicine
Background:
- Mediastinal lymph node staging is crucial for non-small cell lung cancer (NSCLC) treatment planning.
- Positron emission tomography (PET) utilizes 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG) to detect elevated glucose metabolism in malignant tissues.
Purpose of the Study:
- To evaluate the efficacy of FDG-PET scanning in staging thoracic lymph nodes in patients with lung cancer.
- To compare the diagnostic performance of FDG-PET with computed tomography (CT) for N-staging in NSCLC.
Main Methods:
- A study involving 155 patients with focal pulmonary tumors who underwent both preoperative CT and FDG-PET scans.
- Analysis of 116 malignant and 39 benign lesions to determine staging accuracy.
Main Results:
- FDG-PET demonstrated a sensitivity of 88%, specificity of 91%, and accuracy of 89% for N-staging.
- CT yielded lower figures: 77% sensitivity, 76% specificity, and 77% accuracy.
- FDG-PET effectively differentiated between resectable (N1/N2) and unresectable (N3) disease.
Conclusions:
- FDG-PET is a highly effective, noninvasive tool for staging thoracic lymph nodes in lung cancer patients.
- FDG-PET significantly outperforms CT in assessing hilar and mediastinal nodal metastases.
- The findings support FDG-PET's role in guiding operability decisions for NSCLC.